- Home
- WHF vs MIST Comparison
WHF vs MIST Comparison
Compare WHF & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WHF | MIST |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.2M | 163.2M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | WHF | MIST |
|---|---|---|
| Price | $7.02 | $2.07 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $7.75 | ★ $8.50 |
| AVG Volume (30 Days) | 235.7K | ★ 9.9M |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | ★ 26.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $76,339,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.98 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.39 | $0.63 |
| 52 Week High | $11.31 | $3.06 |
Technical Indicators
Market Signals| Indicator | WHF | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 42.50 | 41.82 |
| Support Level | $6.76 | $2.00 |
| Resistance Level | $7.08 | $2.22 |
| Average True Range (ATR) | 0.20 | 0.32 |
| MACD | -0.08 | -0.08 |
| Stochastic Oscillator | 24.07 | 31.72 |
Price Performance
Historical ComparisonAbout WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).